BACKGROUND: For chemosensitivity and resistance assays to be clinically useful in predicting patient outcome, they should require small amounts of tissue and be highly reproducible and reliable. PATIENTS AND METHODS: Expanded tumor cells from transcutaneous biopsies of breast lesions (n=62) were tested for chemoresponse using the cell-based ChemoFx assay. Pathologic complete response (pCR) was determined on a subset of patients (n=34). Assay score and pCR were determined independently in a blinded manner. Logistic regression models were used to select predictors for response. RESULTS: Tumor cells were successfully isolated from 83.9% of patients. Chemoresponse profiles were robust and reproducible with coefficient of variance of <3%. In a limited initial patient outcome correlation, assay score of docetaxel/capecitabine significantly predicted pCR; the cross-validated model was 75% accurate. CONCLUSION: It is feasible to assess the chemoresponsiveness of small breast lesions using the ChemoFx assay to assist in choosing neoadjuvant chemotherapy for breast cancer patients.
BACKGROUND: For chemosensitivity and resistance assays to be clinically useful in predicting patient outcome, they should require small amounts of tissue and be highly reproducible and reliable. PATIENTS AND METHODS: Expanded tumor cells from transcutaneous biopsies of breast lesions (n=62) were tested for chemoresponse using the cell-based ChemoFx assay. Pathologic complete response (pCR) was determined on a subset of patients (n=34). Assay score and pCR were determined independently in a blinded manner. Logistic regression models were used to select predictors for response. RESULTS:Tumor cells were successfully isolated from 83.9% of patients. Chemoresponse profiles were robust and reproducible with coefficient of variance of <3%. In a limited initial patient outcome correlation, assay score of docetaxel/capecitabine significantly predicted pCR; the cross-validated model was 75% accurate. CONCLUSION: It is feasible to assess the chemoresponsiveness of small breast lesions using the ChemoFx assay to assist in choosing neoadjuvant chemotherapy for breast cancerpatients.
Authors: Sarah L Suchy; Rodney J Landreneau; Matthew J Schuchert; Dakun Wang; Paul R Ervin; Stacey L Brower Journal: Cancer Biol Ther Date: 2012-10-31 Impact factor: 4.742
Authors: Patrick D Bhola; Eman Ahmed; Jennifer L Guerriero; Ewa Sicinska; Emily Su; Elizaveta Lavrova; Jing Ni; Otari Chipashvili; Timothy Hagan; Marissa S Pioso; Kelley McQueeney; Kimmie Ng; Andrew J Aguirre; James M Cleary; David Cocozziello; Alaba Sotayo; Jeremy Ryan; Jean J Zhao; Anthony Letai Journal: Sci Signal Date: 2020-06-16 Impact factor: 8.192
Authors: Molly M Morgan; Brian P Johnson; Megan K Livingston; Linda A Schuler; Elaine T Alarid; Kyung E Sung; David J Beebe Journal: Pharmacol Ther Date: 2016-05-21 Impact factor: 12.310
Authors: Kui Shen; Shara D Rice; David A Gingrich; Dakun Wang; Zhibao Mi; Chunqiao Tian; Zhenyu Ding; Stacey L Brower; Paul R Ervin; Michael J Gabrin; George Tseng; Nan Song Journal: PLoS One Date: 2012-07-16 Impact factor: 3.240